Skip to main content

Table 2 The main pharmacokinetic parameters of dihydroartemisinin (DHA) and its metabolite (DHA-Glu) in healthy Chinese subjects with different UGT1A9 (I399C > T) and UGT2B7 (802C > T) genotypes (n = 3-4 for each group) after four recommended oral doses of DHA (80 mg/dose)

From: The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine

 

CL/F1st dose(L/h/kg)

CL/F4th dose(L/h/kg)

CL/F4th dose/CL/F1st dose(90% CI)

MR1st dose

MR4th dose

I399CC/802TT

3.00 ± 0.84

4.72 ± 1.87

1.53 (1.08-1.98)

4.34 ± 0.71

7.90 ± 2.08

I399TT/802CC

3.45 ± 0.71

4.44 ± 1.34

1.39 (1.04-1.74)

5.79 ± 2.72

7.05 ± 4.05

I399TT/802TT

2.84 ± 0.98

4.83 ± 1.54

1.61 (1.35-1.87)

3.89 ± 1.42

8.21 ± 2.15

I399CT/802CT

4.05 ± 1.49

4.60 ± 1.34

1.17 (0.95-1.40)

6.94 ± 3.52

9.25 ± 3.58

  1. MR: metabolic ratio, calculated by AUC DHA-Glu /AUC DHA.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us